Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and …
Over the last 12 months, insiders at Stryker Corporation have bought $0 and sold $289.41M worth of Stryker Corporation stock.
On average, over the past 5 years, insiders at Stryker Corporation have bought $29,617 and sold $135.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 53 shares for transaction amount of $10,173 was made by Doliveux Roch (director) on 2020‑07‑31.
2024-11-15 | Sale | Group President | 514 0.0001% | $391.16 | $201,056 | -1.13% | ||
2024-11-07 | Sale | Chair and CEO | 57,313 0.015% | $368.70 | $21.13M | +4.48% | ||
2024-11-05 | Sale | 230,000 0.0604% | $367.37 | $84.49M | +0.11% | |||
2024-09-17 | Sale | VP, Chief HR Officer | 7,347 0.0019% | $366.98 | $2.7M | -0.72% | ||
2024-09-13 | Sale | VP, Chief HR Officer | 2,121 0.0006% | $370.00 | $784,770 | -2.12% | ||
2024-08-27 | Sale | Group President | 600 0.0002% | $355.00 | $213,000 | +0.78% | ||
2024-08-06 | Sale | 190,000 0.05% | $323.46 | $61.46M | +11.48% | |||
2024-08-02 | Sale | VP, Chief Financial Officer | 20,000 0.0053% | $333.00 | $6.66M | +8.48% | ||
2024-05-22 | Sale | VP, Chief Legal Officer | 2,007 0.0005% | $332.99 | $668,308 | +4.80% | ||
2024-05-15 | Sale | VP, Chief Financial Officer | 10,000 0.0026% | $327.65 | $3.28M | +5.65% | ||
2024-03-07 | Sale | VP, Chief Accounting Officer | 7,690 0.002% | $358.48 | $2.76M | -2.41% | ||
2024-02-09 | Sale | VP, Chief Financial Officer | 9,600 0.0027% | $342.81 | $3.29M | +2.18% | ||
2024-02-06 | Sale | 92,296 0.026% | $339.95 | $31.38M | +2.81% | |||
2024-02-05 | Sale | 201,146 0.0573% | $342.90 | $68.97M | +1.87% | |||
2024-02-02 | Sale | director | 3,273 0.0009% | $341.00 | $1.12M | +2.12% | ||
2023-12-01 | Sale | director | 500 0.0001% | $298.22 | $149,112 | +15.27% | ||
2023-11-28 | Sale | VP, Chief Accounting Officer | 573 0.0002% | $292.28 | $167,477 | +17.18% | ||
2023-11-17 | Sale | Chair and CEO | 56,483 0.0149% | $287.91 | $16.26M | +18.74% | ||
2023-11-16 | Sale | director | 500 0.0001% | $291.92 | $145,962 | +16.79% | ||
2023-11-15 | Sale | director | 500 0.0001% | $287.50 | $143,751 | +20.30% |
Doliveux Roch | director | 22070 0.0058% | $389.81 | 16 | 1 | +9.54% |
The Vanguard Group | $11.26B | 8.26 | 31.46M | +0.99% | +$110.79M | 0.21 | |
BlackRock | $9.39B | 6.89 | 26.24M | +5.29% | +$472.22M | 0.21 | |
State Street | $5.15B | 3.77 | 14.35M | +0.61% | +$31.11M | 0.21 | |
T. Rowe Price | $4.25B | 3.12 | 11.88M | -5.28% | -$236.89M | 0.52 | |
Wellington Management Company | $3.88B | 2.85 | 10.84M | -10.9% | -$474.66M | 0.66 |